Bank of New York Mellon Corp Takes Position in ADMA Biologics Inc $ADMA

Key Points

• Bank of New York Mellon purchased 1.25 million ADMA Biologics shares worth approximately $10.5 million, giving it a 0.54% stake. Institutional investors collectively own 75.68% of the company.
• ADMA reported quarterly EPS of $0.16, in line with estimates, while revenue reached $124.39 million, up 2% year over year but slightly below expectations.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $18.67, compared with the stock’s reported trading price of $9.51.

Bank of New York Mellon Corp purchased a new stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,250,658 shares of the biotechnology company's stock, valued at approximately $10,468,000. Bank of New York Mellon Corp owned approximately 0.54% of ADMA Biologics at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Lido Advisors LLC increased its stake in shares of ADMA Biologics by 3.8% in the 4th quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company's stock valued at $312,000 after buying an additional 629 shares during the period. Cim LLC raised its position in shares of ADMA Biologics by 0.7% during the third quarter. Cim LLC now owns 91,486 shares of the biotechnology company's stock worth $1,341,000 after acquiring an additional 665 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of ADMA Biologics by 28.9% during the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company's stock valued at $57,000 after acquiring an additional 700 shares during the period. Cerity Partners LLC lifted its stake in shares of ADMA Biologics by 1.8% during the second quarter. Cerity Partners LLC now owns 48,572 shares of the biotechnology company's stock valued at $884,000 after acquiring an additional 869 shares during the period. Finally, Legato Capital Management LLC boosted its holdings in ADMA Biologics by 4.7% in the fourth quarter. Legato Capital Management LLC now owns 30,895 shares of the biotechnology company's stock valued at $564,000 after acquiring an additional 1,374 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Trading Up 1.9%

NASDAQ:ADMA opened at $9.51 on Thursday. ADMA Biologics Inc has a 1-year low of $7.21 and a 1-year high of $20.46. The business's 50-day moving average price is $9.12 and its two-hundred day moving average price is $10.36. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of 13.59 and a beta of 0.78.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. The company had revenue of $124.39 million during the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The company's revenue for the quarter was up 2.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.14 EPS. On average, equities analysts expect that ADMA Biologics Inc will post 0.78 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on ADMA. Weiss Ratings reiterated a "hold (c)" rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Zacks Research lowered shares of ADMA Biologics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, August 4th. Mizuho reduced their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating on the stock in a research note on Wednesday, July 15th. Raymond James Financial initiated coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They set an "outperform" rating and a $21.00 price target for the company. Finally, Canaccord Genuity Group dropped their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, May 7th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, ADMA Biologics presently has a consensus rating of "Hold" and a consensus price target of $18.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source